Core Viewpoint - The company, KeFu Medical, has submitted its application for H-share issuance and listing to the Hong Kong Stock Exchange on August 29, 2025, and is awaiting approval from relevant regulatory bodies [1]. Group 1: Listing Progress - KeFu Medical has officially submitted its H-share issuance and listing application to the Hong Kong Stock Exchange [1]. - The approval process requires consent from the Hong Kong Securities and Futures Commission, the Hong Kong Stock Exchange, and the China Securities Regulatory Commission [1]. Group 2: Market Value Management - The company emphasizes that the core support for market value lies in the quality of its operational development and long-term value creation capabilities [1]. - KeFu Medical plans to focus on its main business development, enhancing R&D innovation, production operations, market expansion, and international layout capabilities [1]. - The company aims to solidify its operational fundamentals and enhance its core competitiveness and sustainable development capacity to create long-term stable investment value for shareholders [1]. Group 3: Communication and Disclosure - KeFu Medical commits to adhering to regulatory requirements for information disclosure and strengthening communication with the capital market [1]. - The company encourages investors to stay updated on its operational developments through future announcements [1].
可孚医疗：已于2025年8月29日向香港联交所递交H股发行及上市申请